RecruitingPhase 1Phase 2NCT06099379

Modulation of THC Effects by CBD: a Dose-ranging Study

Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

100 participants

Start Date

Jun 27, 2024

Study Type

INTERVENTIONAL

Conditions

Cannabis THC

Summary

The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.

Eligibility

Min Age: 21 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ∆9-tetrahydrocannabinol for people with cannabis and thc. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 49 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.